NEW YORK, March 7, 2012 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) announced today the recipients of their fifth annual research award, Frontotemporal Degeneration Drug Discovery Program. The goal of the program is to accelerate the development of novel therapies for frontotemporal degeneration (FTD).
The ADDF/AFTD program awarded $300,000 to three academic scientists developing biomarkers for FTD. The award winners are: Adam Boxer, MD, PhD, University of California, San Francisco; William Seeley, MD, University of California, San Francisco; and Charlotte Teunissen, PhD, VU University Medical Center in Amsterdam, Netherlands. An independent panel of 7 experts from the ADDF's Scientific Review Board and AFTD's Medical Advisory Council evaluated 15 applications submitted from around the world.
"To develop effective treatments for FTD, biomarkers are crucially needed to select appropriate patients for clinical trials and to monitor responses to treatments," said Howard Fillit, MD, ADDF Executive Director. "Yet, there are currently no effective biomarkers available. We are optimistic that these three programs will fulfill this unmet need and help advance drug discovery efforts for FTD."
FTD is a devastating form of dementia characterized by profound changes in behavior, personality, language and movement. It is the second most common cause of dementia under the age of 60 years, most frequently having its onset between the ages of 40 and 65. As with Alzheimer's disease, there are no drugs to treat, prevent or cure FTD.
"We continue to be very pleased with the quality of applications for this program," said Susan L-J Dickinson, AFTD Executive Director. "This year's recipients are all engaged in research that offers both caregivers and patients the optimism they ne
|SOURCE Alzheimer's Drug Discovery Foundation|
Copyright©2010 PR Newswire.
All rights reserved